资料显示，迪安诊断技术集团股份有限公司位于浙江省杭州市西湖区金蓬街329号2幢5层，成立日期 2001年9月5日，上市日期2011年7月19日，公司主营业务涉及面向各种综合医院与专科医院、社区卫生 服务中心(站)、乡(镇)卫生院、体检中心、疾病预防控制中心等各级医疗卫生机构,以提供医学诊断服务 外包为核心业务的医学诊断服务整体解决方案。主营业务收入构成为：渠道产品65.34%，诊断服务 34.66%。 1月30日，迪安诊断跌4.63%，成交额11.79亿元。两融数据显示，当日迪安诊断获融资买入额1.12亿 元，融资偿还1.53亿元，融资净买入-4112.89万元。截至1月30日，迪安诊断融资融券余额合计8.32亿 元。 融资方面，迪安诊断当日融资买入1.12亿元。当前融资余额8.30亿元，占流通市值的5.56%，融资余额 超过近一年90%分位水平，处于高位。 融券方面，迪安诊断1月30日融券偿还1.32万股，融券卖出1.01万股，按当日收盘价计算，卖出金额 24.13万元；融券余量7.68万股，融券余额183.48万元，超过近一年60%分位水平，处于较高位。 分红方面，迪安诊断A股上市后累计派现10.99亿元 ...

Group 1 - The core point of the news is that Dian Diagnostics experienced a significant stock price increase of 19.15%, reaching 25.88 CNY per share, with a trading volume of 342 million CNY and a turnover rate of 2.72%, resulting in a total market capitalization of 16.174 billion CNY [1] - Dian Diagnostics is based in Hangzhou, Zhejiang Province, and was established on September 5, 2001. It went public on July 19, 2011. The company specializes in providing medical diagnostic services, focusing on outsourcing solutions for various healthcare institutions, including hospitals and health service centers [1] - The revenue composition of Dian Diagnostics consists of 65.34% from channel products and 34.66% from diagnostic services [1] Group 2 - According to data from mutual funds, Wan Jia Fund has a significant holding in Dian Diagnostics, with the Wan Jia Health Industry Mixed A Fund (010054) reducing its holdings by 58,200 shares in the third quarter, now holding 222,000 shares, which represents 5.47% of the fund's net value, making it the seventh-largest holding [2] - The Wan Jia Health Industry Mixed A Fund was established on September 30, 2020, with a latest scale of 56.9046 million CNY. It has achieved a year-to-date return of 20.73%, ranking 5th out of 9,012 in its category, and a one-year return of 22.31%, ranking 5134 out of 8,157 [2]

Group 1 - The core viewpoint of the news is that Dian Diagnostics has seen a stock price increase of 5.08%, reaching 18.01 CNY per share, with a trading volume of 397 million CNY and a turnover rate of 4.50%, resulting in a total market capitalization of 11.256 billion CNY [1] - Dian Diagnostics, established on September 5, 2001, and listed on July 19, 2011, is based in Hangzhou, Zhejiang Province. The company specializes in providing medical diagnostic service outsourcing solutions to various healthcare institutions, including hospitals, community health service centers, and disease prevention and control centers [1] - The revenue composition of Dian Diagnostics is primarily from channel products (65.34%) and diagnostic services (34.66%) [1] Group 2 - From the perspective of the top ten circulating shareholders, Southern Fund has a fund that ranks among them. The Southern CSI 1000 ETF (512100) reduced its holdings by 40,900 shares in the third quarter, now holding 4.5688 million shares, which accounts for 0.91% of the circulating shares [2] - The Southern CSI 1000 ETF (512100) was established on September 29, 2016, with a latest scale of 76.63 billion CNY. Year-to-date, it has achieved a return of 4.1%, ranking 2067 out of 5493 in its category; over the past year, it has returned 40.84%, ranking 1761 out of 4197; and since inception, it has returned 19.06% [2]

Group 1 - The core viewpoint of the news is that Dian Diagnostics has shown a positive stock performance recently, with a year-to-date increase of 10.35% and a 13.42% rise over the last five trading days [1] - As of January 8, the stock price reached 17.49 yuan per share, with a total market capitalization of 10.931 billion yuan [1] - The company primarily provides medical diagnostic services, with revenue composition of 65.34% from channel products and 34.66% from diagnostic services [1] Group 2 - As of September 30, the number of shareholders decreased by 5.45% to 45,700, while the average circulating shares per person increased by 5.76% to 10,974 shares [2] - For the period from January to September 2025, Dian Diagnostics reported a revenue of 7.566 billion yuan, a year-on-year decrease of 18.28%, and a net profit attributable to shareholders of 56.7048 million yuan, down 56.67% year-on-year [2] - The company has distributed a total of 1.099 billion yuan in dividends since its A-share listing, with 712 million yuan distributed in the last three years [3]

Group 1 - The core viewpoint of the news is that Dian Diagnostics has seen a stock price increase of 5.09%, reaching 15.91 yuan per share, with a trading volume of 1.67 billion yuan and a market capitalization of 99.43 billion yuan as of the report date [1] - Dian Diagnostics, established on September 5, 2001, and listed on July 19, 2011, provides medical diagnostic services primarily to various healthcare institutions, with its main business revenue composition being 65.34% from channel products and 34.66% from diagnostic services [1] Group 2 - Among the top circulating shareholders of Dian Diagnostics, a fund under Yongying Fund ranks first, while the Medical Device ETF (159883) entered the top shareholders in the third quarter, holding 3.0875 million shares, which is 0.62% of the circulating shares [2] - The Medical Device ETF (159883) was established on April 22, 2021, with a current scale of 4.73 billion yuan, showing a year-to-date return of 1.98% and a one-year loss of 1.18% [2]

Core Viewpoint - Dian Diagnostics has shown a significant stock price increase of 48.75% year-to-date, despite a recent decline in revenue and net profit [1][2]. Group 1: Stock Performance - On November 18, Dian Diagnostics' stock rose by 2.23%, reaching 16.52 CNY per share, with a trading volume of 1.17 billion CNY and a turnover rate of 1.43%, resulting in a total market capitalization of 103.25 billion CNY [1]. - The stock has experienced a slight increase of 0.06% over the last five trading days, a 7.97% increase over the last 20 days, and a minor decline of 0.12% over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent occurrence on February 17 [1]. Group 2: Financial Performance - For the period from January to September 2025, Dian Diagnostics reported a revenue of 75.66 billion CNY, reflecting a year-on-year decrease of 18.28%, while the net profit attributable to shareholders was 56.70 million CNY, down 56.67% year-on-year [2]. - Since its A-share listing, the company has distributed a total of 10.99 billion CNY in dividends, with 7.12 billion CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Dian Diagnostics was 45,700, a decrease of 5.45% from the previous period, with an average of 10,974 shares held per shareholder, an increase of 5.76% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 10.56 million shares, a decrease of 4.23 million shares from the previous period [3].

Core Insights - On October 20, Dian Diagnostics experienced a 1.00% increase in stock price with a trading volume of 99.02 million yuan [1] - The company reported a financing buy-in of 10.20 million yuan and a net financing outflow of -2.76 million yuan on the same day [1] - As of October 20, the total financing and securities lending balance for Dian Diagnostics was 610 million yuan, indicating a high level of financing activity [1] Financing Summary - On October 20, Dian Diagnostics had a financing buy-in of 10.20 million yuan, with a current financing balance of 608 million yuan, representing 6.44% of its market capitalization [1] - The financing balance is above the 70th percentile of the past year, indicating a relatively high level of financing [1] - In terms of securities lending, there were no shares repaid, with 1,200 shares sold, amounting to 18,100 yuan at the closing price [1] Company Overview - Dian Diagnostics, established on September 5, 2001, and listed on July 19, 2011, is based in Hangzhou, Zhejiang Province [1] - The company specializes in providing medical diagnostic services, focusing on outsourcing solutions for various healthcare institutions, including hospitals and health service centers [1] - The revenue composition includes 65.34% from channel products and 34.66% from diagnostic services [1] Financial Performance - As of June 30, 2025, Dian Diagnostics reported a revenue of 4.936 billion yuan, a year-on-year decrease of 20.61% [2] - The net profit attributable to shareholders was 10.28 million yuan, reflecting a significant year-on-year decline of 85.68% [2] Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 11.32% to 48,300, while the average number of circulating shares per person increased by 12.77% to 10,376 shares [2] - The company has distributed a total of 1.099 billion yuan in dividends since its A-share listing, with 712 million yuan distributed over the past three years [3] - Notable institutional shareholders include Hong Kong Central Clearing Limited and new entrant招商优势企业混合A, indicating a shift in shareholder composition [3]

Core Viewpoint - The stock of Dian Diagnostics has experienced a decline recently, with a notable drop in trading volume and a significant decrease in revenue and profit year-on-year [1][2]. Financial Performance - As of June 30, 2025, Dian Diagnostics reported a revenue of 4.936 billion yuan, a year-on-year decrease of 20.61% [2]. - The net profit attributable to shareholders was 10.2772 million yuan, reflecting a substantial year-on-year decrease of 85.68% [2]. - The stock price has increased by 35.78% year-to-date, but has seen declines of 5.81% over the last five trading days, 12.22% over the last 20 days, and 3.77% over the last 60 days [1]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 11.32% to 48,300, while the average circulating shares per person increased by 12.77% to 10,376 shares [2]. - The company has distributed a total of 1.099 billion yuan in dividends since its A-share listing, with 712 million yuan distributed over the last three years [3]. Institutional Holdings - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 14.7985 million shares, an increase of 3.4713 million shares from the previous period [3]. - The third-largest circulating shareholder is the newly entered招商优势企业混合A, holding 11 million shares [3]. - The seventh-largest shareholder, 南方中证1000ETF, increased its holdings by 872,500 shares to 4.6097 million shares [3].

Core Viewpoint - The stock of Dian Diagnostics has experienced fluctuations, with a recent decline of 3.00% and a year-to-date increase of 39.83%, indicating volatility in its market performance [1][2]. Company Overview - Dian Diagnostics, established on September 5, 2001, and listed on July 19, 2011, is based in Hangzhou, Zhejiang Province. The company specializes in providing medical diagnostic services, focusing on outsourcing solutions for various healthcare institutions [1]. - The company's revenue composition includes 65.34% from channel products and 34.66% from diagnostic services [1]. Financial Performance - For the first half of 2025, Dian Diagnostics reported a revenue of 4.936 billion yuan, a year-on-year decrease of 20.61%. The net profit attributable to shareholders was 10.2772 million yuan, down 85.68% compared to the previous year [2]. - Since its A-share listing, the company has distributed a total of 1.099 billion yuan in dividends, with 712 million yuan distributed over the last three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 11.32% to 48,300, while the average number of circulating shares per person increased by 12.77% to 10,376 shares [2]. - The top shareholders include Hong Kong Central Clearing Limited, which holds 14.7985 million shares, and new entrant招商优势企业混合A, holding 11 million shares [3].